Sun Pharma shares hit 52-week high as Brazil clears semaglutide injection for diabetes treatment
ADVERTISEMENT
Shares of Sun Pharmaceutical Industries hit 52-week high on Thursday after the company received regulatory approval in Brazil to manufacture and market its semaglutide injection for the treatment of adults with inadequately controlled Type 2 diabetes.
Cheering the news, Sun Pharma shares climbed as much as 1.36% to hit a new 52-week high of ₹2,017 on the BSE, taking its market capitalisation to over ₹4.82 lakh crore. The pharma heavyweight has rebounded 30% from its 52-week low of 1,547.25 on September 26, 2025. The stock has risen 17% in the calendar year 2026, while it added over 8% in a month.
In an exchange filing last evening, Sun Pharma said it has secured approval from the Brazilian Health Regulatory Agency (ANVISA) for its semaglutide injection, which will be used as an adjunct to diet and exercise for adults with inadequately controlled Type 2 diabetes mellitus.
The company plans to launch the product in Brazil over the next few days in partnership with Hypera Pharma, one of the country's leading pharmaceutical companies.
The drug will be available as a pre-filled, multi-dose injectable pen in two strengths - 2 mg/1.5 mL and 4 mg/3 mL - enabling flexible, once-weekly dosing.
"The approval of semaglutide in Brazil expands access to an evidence-based treatment option for people living with inadequately controlled Type 2 diabetes. It reflects the strength of our development and manufacturing capabilities and our commitment to delivering high-quality medicines across global markets," said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.
Digvijay Singh, Regional Head, Brazil & LATAM, said the approval strengthens the company's diabetes portfolio in one of Latin America's largest pharmaceutical markets.
"This approval marks an important step in strengthening our diabetes portfolio in Brazil. We look forward to working closely with our partner to make this treatment option available to patients and support better diabetes care across the country," he said.
According to the company, the Brazilian semaglutide injectable market is valued at around $413 million, based on IQVIA MAT data for June 2026.
In a separate development, Sun Pharma last week informed stock exchanges that shareholders of Organon & Co. had approved proposals related to the company's proposed acquisition by Sun Pharmaceutical Holdings USA, an indirect wholly owned subsidiary of Sun Pharma. The shareholder nod marks a key milestone in the $11.75-billion all-cash deal announced in April, although the transaction remains subject to customary closing conditions, including regulatory approvals.
The acquisition is expected to close in early 2027 and will strengthen Sun Pharma's position among the world's top 25 pharmaceutical companies, with combined annual revenue of around $12.4 billion. It will also make the company a top-three player globally in women's health and among the top seven in biosimilars.
Organon, which was spun off from Merck (MSD outside the U.S. and Canada) in 2021, operates in over 140 countries and reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion for 2025.
(DISCLAIMER: The views and opinions expressed by investment experts on fortuneindia.com are either their own or of their organisations, but not necessarily that of fortuneindia.com and its editorial team. Readers are advised to consult certified experts before taking investment decisions.)